Skip to main content
S&P 5007,670.84-0.17%DOW51,349.92-0.26%NASDAQ26,797.54-0.09%BTC$83,776.00-0.24%ETH$2,689.31-0.97%GOLD$4,215.10+0.85%OIL$90.62+1.39%
Smart Investors Daily
DA

NASDAQ · DARE

Daré Bioscience, Inc.

Healthcare · Biotechnology

$0.82

Up+$0.07 (+8.67%)

Updated Sep 30, 2026, 2:08 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.81M
P/E ratio
-1.52
Dividend yield
0.00%
52-week range
$0.69 – $3.78
Volume
644.39K
Avg. volume
140.35K

Price performance · DARE

DARE price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 29, 2026

DARE closed at $0.82 after 20 trading sessions, up 5.82% for the selected period.

Last close
$0.82
Period change
+5.82%
Period low
$0.71
Period high
$0.85
Daily close
View OHLC price history
DARE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 29, 2026$0.7869$0.8671$0.7356$0.815644.39K
Sep 28, 2026$0.79$0.816$0.7012$0.75698.47K
Sep 25, 2026$0.77$0.7895$0.7458$0.7755119.24K
Sep 24, 2026$0.8023$0.8456$0.7117$0.7405469.51K
Sep 23, 2026$0.85$0.8699$0.80$0.8074100.04K
Sep 22, 2026$0.81$0.88$0.8099$0.85245.72K
Sep 21, 2026$0.82$0.8399$0.796$0.81279.93K
Sep 18, 2026$0.7925$0.81$0.7655$0.7843229.16K
Sep 17, 2026$0.7445$0.7759$0.7445$0.7478153.93K
Sep 16, 2026$0.732$0.7593$0.724$0.7255135.5K
Sep 15, 2026$0.7413$0.7713$0.72$0.7301109.23K
Sep 14, 2026$0.7064$0.75$0.691$0.7363426.37K
Sep 11, 2026$0.717$0.7233$0.705$0.70693.72K
Sep 10, 2026$0.70$0.7247$0.70$0.7051103.44K
Sep 9, 2026$0.729$0.7299$0.691$0.7166175.32K
Sep 8, 2026$0.7299$0.737$0.701$0.713191.71K
Sep 4, 2026$0.70$0.7573$0.70$0.721437.48K
Sep 3, 2026$0.7512$0.779$0.69$0.7131450.3K
Sep 2, 2026$0.78$0.797$0.74$0.74249.08K
Sep 1, 2026$0.744$0.797$0.7301$0.7702462.69K

Latest DARE news

The latest Smart Investors Daily articles mentioning DARE.

Stock researchCompany · Overview

Company

OverviewForecastEarnings — requires Earnings Calls and Results accessDividend — requires Dividend Research accessFinancials

Market Activity

OptionsInsider Trades — requires Insider Buying and Selling accessShort InterestInstitutional Ownership — requires Institutional Ownership accessSentiment

DARE research

Overview

Company profile and research snapshot.

Company profile

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
DARE recent ratings
DateFirmRatingTarget
Dec 2, 2025HC Wainwright & Co.Buy—
Sep 4, 2025Maxim GroupBuy—
Apr 1, 2025HC Wainwright & Co.Buy—
Dec 17, 2024HC Wainwright & Co.Buy—
Nov 15, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a

Benzinga · Sep 14, 2026

Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose

The article, titled, "An open-label, single-dose, randomized, parallel-group study of the safety and relative bioavailability of topical sildenafil cream vs oral sildenafil in healthy male adults," discusses

Yahoo · Sep 11, 2026

Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand

View the video webcast here SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive

Yahoo · Aug 31, 2026

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's heal

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By